Kate Hardey

Life Sciences

• Vyaire Medical in the sale of the Vyaire Respiratory Diagnostics (RDx) business unit, a manufacturer of respiratory diagnostic products, to Trudell Medical Limited
• Eli Lilly and Company (NYSE: LLY) in its $3.2 billion acquisition of Morphic (NASDAQ: MORF), a biotechnology company
• Ingersoll Rand Inc., a global provider of mission-critical flow creation and industrial solutions, on the $2.325 billion acquisition of ILC Dover from New Mountain Capital
• Dechra Pharmaceuticals in its $520 million acquisition of Invetx, a provider of protein-based animal health therapeutics, from Novo Holdings
• CapVest Partners-backed Calyx in its $115 million acquisition of Invicro, a provider of imaging biomarker services, from REALM IDx
• Phibro Animal Health Corporation (NASDAQ: PAHC) in its pending $350 million acquisition of medicated feed additive and water soluble product portfolios from Zoetis (NYSE: ZTS)
• CapVest Partners-backed Calyx in its $115 million acquisition of Invicro, a provider of imaging biomarker services, from REALM IDx
• Montagu Private Equity in its $700 million acquisition of the Medical Device Components business from Johnson Matthey (LSE: JMAT)
• Carlisle Companies (NYSE: CSL) in its $2.025 billion sale of Carlisle Interconnect Technologies to Amphenol (NYSE: APH)
• AbbVie (NYSE: ABBV) in its $8.7 billion acquisition of Cerevel Therapeutics (NASDAQ: CERE), a neuroscience drug company
• Nordic Capital in its acquisition of IntegriChain, a platform for pharma commercialization and market access, from Accel-KKR
• KKR- and Everstone Capital-backed Slayback Pharma, a provider of generic and specialty pharmaceutical products, in its sale to Azurity Pharmaceuticals.
• Eli Lilly and Company (NYSE: LLY) in its $1.4 billion acquisition of POINT Biopharma (NASDAQ: PNT), a radiopharmaceutical company
• FFL Partners in its investment in Johnson County Clin-Trials, a clinical research site platform serving pharmaceutical and biotechnology companies and contract research organizations
• THL Partners in its investment in Red Nucleus, a provider of strategic services across the entire life sciences product cycle
• GTCR in its pending $627 million acquisition of Surmodics (NASDAQ: SRDX), a provider of medical device and in vitro diagnostic technologies
• Avista Healthcare Partners in its acquisition of Trillium Health Care Products, a contract development and manufacturing organization of branded over-the-counter products, from New Water Capital
• Aterian Investment Partners in the recapitalization of CPL, a contract development manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms

Healthcare Technology

• Bansk Group in its acquisition of Foundation Wellness, a provider a consumer health & wellness platform for orthotics and other footcare-focused solutions, from Gridiron Capital
• GTCR-backed Cloudbreak Health in its acquisition of Voyce, a provider of language interpretation services
• GTCR on the proposed $180 million acquisition of Cloudbreak Health, LLC, a leading provider of tech-enabled, healthcare-focused language interpretation services
• L Catterton in its $680 million acquisition of Thorne HealthTech (NASDAQ: THRN), a provider of health and wellness solutions

Food & Beverage

• Wind Point Partners in the sale of Handgards, a provider of disposable food safety and hygiene-oriented products for the foodservice industry, to Wynnchurch Capital
• SKKY Partners in its investment in TRUFF, a brand of premium condiments and truffle infused products
• Clayton, Dubilier & Rice in its pending EUR 16 billion acquisition of Opella, a provider of over-the-counter drugs and vitamins, minerals and supplements, from Sanofi (XPAR: SAN; NASDAQ: SNY)
• Sycamore Partners in its acquisition of Playa Bowls, a super fruit bowl franchise restaurant, from Tamarix Equity Partners and Pacific General

Partner, McGuireWoods LLP

Senior Counsel – Healthcare Regulatory, GE Capital Healthcare Financial Services

Hospital Counsel, MedStar Health

Kate served as a volunteer board member for the Domestic Violence Legal Empowerment and Appeals Project (DV LEAP) from January 2014 to June 2022. DV LEAP provides a stronger voice for justice by fighting to overturn unjust trial court outcomes, advancing legal protections for victims of domestic violence and their children through expert appellate advocacy, training lawyers, psychologists and judges on best practices, and spearheading domestic violence litigation in the Supreme Court.